Outlook Therapeutics announced FDA approval of the first branded bevacizumab for wet AMD, overcoming a prior 2023 rejection. The drug is dosed...
Outlook Therapeutics announced FDA approval of the first branded bevacizumab for wet AMD, overcoming a prior 2023 rejection. The drug is dosed...
A new scientific statement reviews evidence on caffeinated coffee and cardiovascular health. While moderate coffee consumption may lower risks of...
Patients using Sanofi's Lantus Solostar insulin pen face supply difficulties as increased demand strains availability. Sanofi acknowledges the issue...